The spin-off from the University of Münster will use the funds raised to accelerate business development, set up biotechnological mass production of dipeptides and launch the first finished products on the market.
It will also look to set up its own production capacities at the Technology Park in Münster.
The company was founded by Dr Ahmed Sallam in June 2012, together with Dr Martin Krehenbrink from the University of Oxford.
“There is great worldwide demand for improving the effect of nutraceuticals, animal feed, or cosmetics via innovative supplements,” said Marcel Vonnahme, investment manager at eCAPITAL.
“With its patented biotechnological process for the production of dipeptides Cysal has a clear unique selling proposition on this market.
“With its biotechnological expertise the company possesses the skills required to produce these substances quicker, inexpensively and more resource efficiently than is the case in conventional production methods,” he added.
Cysal is targeting the pharmaceuticals, food supplements, and cosmetics sectors as well as in the field of veterinary medicine.
It currently works with cforporate partners inclyuding Menapharm Deutschland and Cilian.
Earlier this month High Tech Gründerfonds joined Seedfonds Baden-Wuerttemberg and private investor Günter Lang to invest in German robotics company Synapticon.
Copyright © 2012 AltAssets